AstraZeneca's Imfinzi regimen cuts bladder cancer death risk by 42% in VOLGA trial
AstraZeneca says its Phase III VOLGA trial met primary endpoints, cutting event-free survival risk by 49% and death risk by 42% in MIBC.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, citing AstraZeneca's press release distributed via BusinessWire, the perioperative combination of Imfinzi with neoadjuvant enfortumab vedotin met the Phase III VOLGA endpoints in muscle-invasive bladder cancer (MIBC).
The risk of event-free survival (EFS) fell by 49% (HR 0.51; p<0.0001), while the risk of death fell by 42% (HR 0.58; p=0.0027). Two-year EFS stood at 64% versus 45%, and two-year overall survival at 78% versus 69%. Median EFS and OS have not yet been reached. The FDA has granted Priority Review.
why it matters
The data extend use of the drug to patients who are ineligible for cisplatin and could speed a U.S. approval and inclusion in clinical guidelines. For investors, the results signal potential revenue growth in AstraZeneca's oncology franchise, though the actual effect depends on regulatory timing.
market impact
AZN: possible U.S. approval would widen the Imfinzi market, supporting the company's oncology portfolio
tags
instruments
sources
- AstraZeneca (AZN) Hits EFS, OS in VOLGA; Cuts Death Risk 42% in MIBC — TradingView, 24 October 2026 at 14:30 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗